RBC Capital maintains Legend Biotech at Outperform, lowers price target to $50 from $56
RBC Capital kept Legend Biotech's rating at Outperform but reduced its price target to $50 from $56, a 10.7% cut. The new target suggests a 145.0% upside from the stock's Nov 10 close of $20.41.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short-term selling pressure but leaves room for upside if upcoming catalysts are positive.
Market read
Analyst price target change is a direct catalyst for short-term price movement in LGND.
What to watch
Upcoming clinical trial data could offset the target reduction.
Background
RBC Capital maintains an Outperform rating but reduces the price target, indicating a nuanced view of the company's prospects.
Market effects
Minor impact on biotech sector as analyst coverage shifts.
Limited to U.S. biotech investors.
Low global relevance.
Counterpoint
Some investors may view the cut as an overreaction and see upside potential.
Key entities
- companyLegend Biotech
US-listed biotech firm (NASDAQ: LGND).
- analystRBC Capital
Equity research firm providing the rating change.


